

### **LISTING OF CLAIMS**

1. (Currently amended) A method comprising topically administering a composition to an eye of a mammal in need thereof, said method being effective in delivering a therapeutically effective amount of a therapeutically active agent to a structure or combination of structures of the eye which include the vitreous humor and structures posterior to the vitreous; said composition comprising:
  - a. an effective amount of the therapeutically active agent, or a pharmaceutically acceptable salt or prodrug thereof, to provide a therapeutically effective amount of the therapeutically active agent to said structure or combination of structures of the eye, and
  - b. an effective amount of a cyclodextrin derivative to provide said therapeutically effective amount of said therapeutically active agent to said structure or combination of structures of the eyewherein the cyclodextrin derivative is selected from the group consisting of hydroxypropyl- $\beta$ -cyclodextrin, hydroxypropyl- $\gamma$ -cyclodextrin, sulfobutylether- $\beta$ -cyclodextrin, and sulfobutylether- $\gamma$ -cyclodextrin, hydroxyethyl- $\beta$ -cyclodextrin, hydroxyethyl- $\gamma$ -cyclodextrin, dihydroxypropyl- $\beta$ -cyclodextrin, glucosyl- $\beta$ -cyclodextrin, diglucosyl- $\beta$ -cyclodextrin, maltosyl- $\beta$ -cyclodextrin, maltosyl- $\gamma$ -cyclodextrin, maltotriosyl- $\beta$ -cyclodextrin, maltotriosyl- $\gamma$ -cyclodextrin, dimaltosyl- $\beta$ -cyclodextrin, and combinations thereof.
2. (Original) The method of claim 1 wherein said mammal is a human.
3. (Original) The method of claim 1 wherein said therapeutically active agent, or salt or prodrug thereof, is water-insoluble.
4. (Original) The method of claim 1 wherein said therapeutically active agent, or salt or prodrug thereof, is water-soluble.
5. (Original) The method of claim 1 wherein said therapeutically active agent is not administered to reduce intraocular pressure.
6. (Original) The method of claim 1 wherein said therapeutically active agent is not administered to treat allergic conjunctivitis.

7. (Original) The method of claim 1 wherein said therapeutically active agent is not administered to treat dry eye.
8. (Original) The method of claim 1 wherein said therapeutically active agent is not administered to treat a condition affecting the front of the eye.
9. (Original) The method of claim 1 comprising a  $\beta$ -cyclodextrin derivative.
10. (Original) The method of claim 1 comprising a  $\beta$ -cyclodextrin derivative and a water-soluble polymer.
11. (Original) The method of claim 1 comprising prednisolone acetate, hydroxypropyl- $\beta$ -cyclodextrin, and hydroxypropylmethylcellulose.
12. (Original) The method of claim 1 comprising a  $\gamma$ -cyclodextrin derivative.
13. (Original) The method of claim 5 comprising prednisolone acetate.
14. (Original) The method of claim 5 wherein said cyclodextrin derivate is hydroxypropyl- $\gamma$ -cyclodextrin.
15. (Original) The method of claim 5 which further comprises a cellulose derivative.
16. (Original) The method of claim 5 which further comprises hydroxypropylmethylcellulose having a concentration less than 1%.
17. (Original) The method of claim 5 comprising from 0.05% to 0.4% hydroxypropylmethylcellulose.
18. (Original) The method of claim 5 comprising about from 0.1% to 0.25% hydroxypropylmethylcellulose.
19. (Currently amended) A pharmaceutical product comprising a solution comprising a therapeutically active agent, or a pharmaceutically active salt or a prodrug thereof, and a cyclodextrin derivative, wherein said solution has an ophthalmically acceptable pH, and wherein the cyclodextrin derivative is selected from the group consisting of hydroxypropyl- $\beta$ -cyclodextrin, hydroxypropyl- $\gamma$ -cyclodextrin, sulfobutylether- $\beta$ -cyclodextrin, and sulfobutylether- $\gamma$ -cyclodextrin, hydroxyethyl- $\beta$ -cyclodextrin, hydroxyethyl- $\gamma$ -cyclodextrin, dihydroxypropyl- $\beta$ -cyclodextrin, glucosyl- $\beta$ -cyclodextrin, diglucosyl- $\beta$ -cyclodextrin, maltosyl- $\beta$ -cyclodextrin, maltosyl- $\gamma$ -cyclodextrin, maltotriosyl- $\beta$ -cyclodextrin, maltotriosyl- $\gamma$ -cyclodextrin, dimaltosyl- $\beta$ -cyclodextrin, and combinations thereof;

a container suitable for dispensing drops of said solution to the eye of a mammal in need of treatment by said therapeutically active agent, a pharmaceutically active salt or prodrug thereof ~~prodrug~~, and

a package which indicates that said product is useful for treatment of a disease or condition affecting the back of the eye.

20. (Previously amended) A composition comprising an effective amount of a therapeutically active agent or a pharmaceutically acceptable salt or prodrug thereof, and

an effective amount of a cyclodextrin derivative;

wherein the cyclodextrin derivative is selected from the group consisting of hydroxypropyl- $\beta$ -cyclodextrin, hydroxypropyl- $\gamma$ -cyclodextrin, sulfobutylether- $\beta$ -cyclodextrin, and sulfobutylether- $\gamma$ -cyclodextrin, hydroxyethyl- $\beta$ -cyclodextrin, hydroxyethyl- $\gamma$ -cyclodextrin, dihydroxypropyl- $\beta$ -cyclodextrin, glucosyl- $\beta$ -cyclodextrin, diglucosyl- $\beta$ -cyclodextrin, maltosyl- $\beta$ -cyclodextrin, maltosyl- $\gamma$ -cyclodextrin, maltotriosyl- $\beta$ -cyclodextrin, maltotriosyl- $\gamma$ -cyclodextrin, dimaltosyl- $\beta$ -cyclodextrin, and combinations thereof;

wherein the amount of the therapeutically active agent or salt or prodrug thereof and the amount of the cyclodextrin are effective to deliver a therapeutically effective amount of said therapeutically active agent to a structure or combination of structures of the eye which include the vitreous humor and structures posterior to the vitreous; wherein the therapeutically effective amount of the therapeutically active agent is delivered by administering said composition topically.

21. (Currently Amended) The ~~composition~~ product of claim 19 wherein said therapeutically active agent is not intended to reduce intraocular pressure.

22. (Currently Amended) The ~~method~~ product of claim 19 wherein said therapeutically active agent is not intended to treat a condition affecting the front of the eye.

23. (Previously amended) The composition of claim 20 comprising from 0.1% to 2% prednisolone acetate and from 1% to 30% of the cyclodextrin derivative.

24. (Original) The composition of claim 23 comprising a  $\beta$ -cyclodextrin derivative.

25. (Original) The composition of claim 23 comprising a  $\gamma$ -cyclodextrin derivative.

26. (Previously presented) The method of claim 1, wherein the therapeutically active agent is a corticosteroid.

27. (Previously presented) The composition of claim 20, wherein the therapeutically active agent is a corticosteroid.